Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03911388 · ClinicalTrials.gov registry record · Phase 1
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
A Phase 1 study of Neoplasms and Glioblastoma Multiforme, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT03911388 is a Phase 1 study of Neoplasms and Glioblastoma Multiforme that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03911388, a Phase 1 study of Neoplasms and Glioblastoma Multiforme, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Conditions Studied
Interventions
- BIOLOGICAL G207
Study Locations (3)
Alabama
- Children's of Alabama - Birmingham
Missouri
- St. Louis Children's Hospital - St Louis
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-09-12 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03911388
The ClinicalTrials.gov registry entry for NCT03911388 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which G207 is the first listed.
NCT03911388 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT03911388 about?
NCT03911388 is a clinical study titled "HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors". This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-t...
What is the current status of trial NCT03911388?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-09-12. Estimated completion is 2027-09-01.
What conditions does trial NCT03911388 study?
This clinical trial studies the following conditions: Neoplasms, Glioblastoma Multiforme, Astrocytoma, Neoplasms, Brain, Glioblastoma of Cerebellum.
What interventions are being tested in trial NCT03911388?
The interventions under investigation include: G207 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03911388?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03911388 being conducted?
This trial has 3 study locations across Alabama, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.